Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: two different patterns of myocardial perfusion associated with degree of hypertrophy.
OBJECTIVE
The aim of this study was to quantitatively measure regional and global myocardial blood flow and coronary reserve in hypertensive patients without coronary artery disease and to assess the correlation with left ventricular mass.


BACKGROUND
The effect of left ventricular hypertrophy on regional vasodilating coronary capability in arterial hypertension is controversial, and no quantitative method has been applied to assess a possible correlation.


METHODS
Positron emission tomography was performed in 50 untreated hypertensive patients and 13 normotensive subjects. Blood flow at baseline and after dipyridamole was globally and regionally measured by using nitrogen-13 ammonia; coronary reserve and resistance were calculated. Left ventricular mass was assessed by two-dimensional echocardiography.


RESULTS
In hypertensive patients, flow at baseline was similar to that of normotensive subjects (p = 0.21), but values were reduced after pharmacologic vasodilation (p < 0.05). This impairment of maximal coronary flow was not correlated with left ventricular mass (p = 0.13). Among hypertensive patients, we identified a group with a homogeneous distribution of perfusion and a group with a heterogeneous flow pattern. Flow was globally reduced in the former group, but it was abnormal only at the site of perfusion defects in the latter. Patients with regional defects showed the highest likelihood of having an increased left ventricular mass.


CONCLUSIONS
In arterial hypertension, left ventricular mass is not correlated with global myocardial blood flow. Nevertheless, patients with ventricular hypertrophy are likely to show a heterogeneous flow pattern with regional defects and almost normal blood flow in nonaffected regions. In hypertensive patients with a homogeneous perfusion pattern during stress, myocardial blood flow frequently shows a diffuse reduction.
Gimelli
A
A
CNR Institute of Clinical Physiology, Pisa, Italy.
Schneider-Eicke
J
J
Neglia
D
D
Sambuceti
G
G
Giorgetti
A
A
Bigalli
G
G
Parodi
G
G
Pedrinelli
R
R
Parodi
O
O
D000328:Adult; D000368:Aged; D000641:Ammonia; D000704:Analysis of Variance; D016009:Chi-Square Distribution; D003326:Coronary Circulation; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000503:physiopathology; D004176:Dipyridamole; D004452:Echocardiography; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology*; D016018:Least-Squares Analysis; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009590:Nitrogen Radioisotopes; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D014655:Vascular Resistance / Q000502:physiology; D014664:Vasodilation / Q000502:physiology; D014665:Vasodilator Agents
D009590:Nitrogen Radioisotopes; D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; D004176:Dipyridamole; D000641:Ammonia